These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22345281)

  • 1. Isolated lung perfusion with gemcitabine combined with radiotherapy: no additional lung toxicity in an experimental model.
    Van Thielen J; Wittock A; Hendriks J; den Hengst W; De Pooter C; Van den Weyngaert D; Pauwels P; Van Schil P
    Eur J Cardiothorac Surg; 2012 Oct; 42(4):712-8. PubMed ID: 22345281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity and efficacy of isolated lung perfusion with gemcitabine in a rat model of pulmonary metastases.
    Van Putte BP; Hendriks JM; Romijn S; De Greef K; Van Schil PE
    Thorac Cardiovasc Surg; 2006 Mar; 54(2):129-33. PubMed ID: 16541356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination chemotherapy with gemcitabine with isolated lung perfusion for the treatment of pulmonary metastases.
    Van Putte BP; Hendriks JM; Romijn S; Pauwels B; Vermorken JB; Van Schil PE
    J Thorac Cardiovasc Surg; 2005 Jul; 130(1):125-30. PubMed ID: 15999051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute and delayed toxicity of gemcitabine administered during isolated lung perfusion: a preclinical dose-escalation study in pigs.
    Pagès PB; Derangere V; Bouchot O; Magnin G; Charon-Barra C; Lokiec F; Ghiringhelli F; Bernard A
    Eur J Cardiothorac Surg; 2015 Aug; 48(2):228-35. PubMed ID: 25414426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolated lung perfusion with gemcitabine in a rat: pharmacokinetics and survival.
    Van Putte BP; Hendriks JM; Romijn S; Pauwels B; Friedel G; Guetens G; De Bruijn EA; Van Schil PE
    J Surg Res; 2003 Feb; 109(2):118-22. PubMed ID: 12643852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified approach of administering cytostatics to the lung: more efficient isolated lung perfusion.
    van Putte BP; Hendriks JM; Guetens G; de Boeck G; de Bruijn EA; van Schil PE; Folkerts G
    Ann Thorac Surg; 2006 Sep; 82(3):1033-7. PubMed ID: 16928530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics after pulmonary artery perfusion with gemcitabine.
    Van Putte BP; Hendriks JM; Romijn S; Pauwels B; De Boeck G; Guetens G; De Bruijn E; Van Schil PE
    Ann Thorac Surg; 2003 Oct; 76(4):1036-40; discussion 1040. PubMed ID: 14529980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of hematologic toxicity in older adults treated with gemcitabine or a gemcitabine-containing regimen in routine clinical practice: a multicenter retrospective cohort study.
    Crombag MR; de Vries Schultink AH; Schellens JH; Beijnen JH; Huitema AD
    Drugs Aging; 2014 Oct; 31(10):737-47. PubMed ID: 25216600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regional chemotherapy in locally advanced pancreatic cancer: RECLAP trial.
    Davis JL; Pandalai P; Ripley RT; Langan RC; Steinberg SM; Walker M; Toomey MA; Levy E; Avital I
    Trials; 2011 May; 12():129. PubMed ID: 21595953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective pulmonary artery perfusion followed by blood flow occlusion: new challenge for the treatment of pulmonary malignancies.
    Grootenboers MJ; Schramel FM; van Boven WJ; Hendriks JM; van Schil PE; De Wit PE; Pasterkamp G; Folkerts G; van Putte BP
    Lung Cancer; 2009 Mar; 63(3):400-4. PubMed ID: 18657338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma.
    Budiharto T; Haustermans K; Van Cutsem E; Van Steenbergen W; Topal B; Aerts R; Ectors N; Bielen D; Vanbeckevoort D; Goethals L; Verslype C
    Radiat Oncol; 2008 Sep; 3():30. PubMed ID: 18808686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer.
    Zwitter M; Kovac V; Smrdel U; Strojan P
    J Thorac Oncol; 2006 Sep; 1(7):662-6. PubMed ID: 17409933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine).
    Fields MT; Eisbruch A; Normolle D; Orfali A; Davis MA; Pu AT; Lawrence TS
    Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):785-91. PubMed ID: 10837965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. External beam radiotherapy plus 24-hour continuous infusion of gemcitabine in unresectable pancreatic carcinoma: long-term results of a phase II study.
    Mattiucci GC; Morganti AG; Valentini V; Ippolito E; Alfieri S; Antinori A; Crucitti A; D'Agostino GR; Di Lullo L; Luzi S; Mantini G; Smaniotto D; Doglietto GB; Cellini N
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):831-8. PubMed ID: 19427747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Schedule-dependent antitumor effect of gemcitabine in in vivo model system.
    Braakhuis BJ; Ruiz van Haperen VW; Boven E; Veerman G; Peters GJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):42-6. PubMed ID: 7481844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly short infusions of gemcitabine are not associated with suppression of lymphatic activity in patients with solid tumors.
    Daikeler T; Maas K; Hartmann JT; Kanz L; Bokemeyer C
    Anticancer Drugs; 1997 Jul; 8(6):643-4. PubMed ID: 9300581
    [No Abstract]   [Full Text] [Related]  

  • 18. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
    Ke QH; Zhou SQ; Yang JY; Du W; Liang G; Lei Y; Luo F
    World J Gastroenterol; 2014 Oct; 20(38):13987-92. PubMed ID: 25320537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine concurrent with thoracic radiotherapy after induction chemotherapy with gemcitabine/vinorelbine in locally advanced non-small cell lung cancer: a phase I study.
    Gagel B; Piroth M; Pinkawa M; Reinartz P; Zimny M; Fischedik K; Stanzel S; Breuer C; Skobel E; Asadpour B; Schmachtenberg A; Buell U; Eble MJ
    Strahlenther Onkol; 2006 May; 182(5):263-9. PubMed ID: 16673059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Locoregional/systemic chemotherapy of locally advanced/metastasized pancreatic cancer with a combination of mitomycin-C and gemcitabine and simultaneous follow-up by imaging methods and tumor markers.
    Klapdor R; Seutter E; Lang-Pölckow EM; Reichle H; Hinrichs A
    Anticancer Res; 1999; 19(4A):2459-69. PubMed ID: 10470175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.